Management of Severe Abemaciclib-induced Liver Dysfunction: Feasibility of Switching to Palbociclib

SHINYA TAKADA; KENGO UMEHARA; KENICHI WATANABE

doi:10.21873/invivo.14217

Case ReportCase Reports

Open Access

Management of Severe Abemaciclib-induced Liver Dysfunction: Feasibility of Switching to Palbociclib

SHINYA TAKADA, KENGO UMEHARA and KENICHI WATANABE

In Vivo January 2026, 40 (1) 532-537; DOI: https://doi.org/10.21873/invivo.14217

SHINYA TAKADA

1Department of Pharmacy, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: snowman198019{at}gmail.com

KENGO UMEHARA

1Department of Pharmacy, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

KENICHI WATANABE

2Department of Breast Surgery, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Info & Metrics
PDF

Article Figures & Data

Figures

Tables

Download figure
Open in new tab
Download powerpoint
Download figure
Open in new tab
Download powerpoint
Figure 1.
Timeline of drug administration and ALT levels in the five reported cases. ALT: Alanine aminotransferase; ABE: abemaciclib; ANA: anastrozole; FUL: fulvestrant; LET: letrozole; PAL: palbociclib.

Tables

Figures

PreviousNext

In this issue

In Vivo

Vol. 40, Issue 1

January-February 2026

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Ed Board (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on In Vivo.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Management of Severe Abemaciclib-induced Liver Dysfunction: Feasibility of Switching to Palbociclib

Message Subject (Your Name) has sent you a message from In Vivo

Message Body (Your Name) thought you would like to see the In Vivo web site.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Math question * 1 + 0 =

Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

Citation Tools

Management of Severe Abemaciclib-induced Liver Dysfunction: Feasibility of Switching to Palbociclib

SHINYA TAKADA, KENGO UMEHARA, KENICHI WATANABE

In Vivo Jan 2026, 40 (1) 532-537; DOI: 10.21873/invivo.14217

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Reprints and Permissions

Management of Severe Abemaciclib-induced Liver Dysfunction: Feasibility of Switching to Palbociclib

SHINYA TAKADA, KENGO UMEHARA, KENICHI WATANABE

In Vivo Jan 2026, 40 (1) 532-537; DOI: 10.21873/invivo.14217

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Jump to section

Article
Figures & Data
Info & Metrics
PDF

Cited By...

No citing articles found.

Google Scholar

Keywords

breast cancer
hepatotoxicity
drug-induced liver dysfunction
abemaciclib
palbociclib
CDK4/6 inhibitors

Main menu

User menu

Search

Management of Severe Abemaciclib-induced Liver Dysfunction: Feasibility of Switching to Palbociclib

Article Figures & Data

Figures

Tables

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Keywords